B7-H3 overexpressing BC cells were found to be less susceptible to the effects of the PI3K/Akt/mTOR pathway inhibitors, triciribidine and everolimus, compared to B7-H3 knock-out counterparts [142]. This evidence concerns the gene CD276 and breast cancer.